New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
08:38 EDTROSGRosetta Genomics announces its cancer test received provider status
Rosetta Genomics announces the Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services, a subsidiary of Highmark. This test for the identification of the tumor origin in Cancer of Unknown or Uncertain Primary is now available to eligible Highmark Health Services members as an in-network service based on the individual member's benefits.
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:00 EDTROSGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CECO Environmental (CECE) upgraded on several positive catalysts at Roth Capital... EMC (EMC) upgraded to Outperform from Market Perform at Bernstein... Fleetmatics (FLTX) upgraded to Overweight from Neutral at Piper Jaffray... NorthStar Asset Management (NSAM) upgraded to Buy from Hold at MLV & Co.... Penn National (PENN) upgraded to Overweight from Neutral at JPMorgan... Rosetta Genomics (ROSG) upgraded to Buy from Hold at Cantor... Ulta Salon (ULTA) upgraded to Buy from Neutral at Nomura... Xcel Energy (XEL) upgraded to Buy from Hold at Argus.
09:14 EDTROSGOn The Fly: Pre-market Movers
Subscribe for More Information
06:33 EDTROSGRosetta Genomics upgraded to Buy from Hold at Cantor
Subscribe for More Information
April 16, 2015
11:16 EDTROSGRosetta Genomics receives patent allowance for cancer of origin diagnostic assay
Subscribe for More Information
April 9, 2015
12:48 EDTROSGRosetta Genomics up 25% after agreeing to acquire PersonalizeDx
Subscribe for More Information
12:18 EDTROSGRosetta Genomics agrees to acquire PersonalizeDx
Rosetta Genomics announces it has agreed to acquire CynoGen, or PersonalizeDx, from Prelude Corporation, a Fjord Ventures portfolio company. The acquisition of PersonalizeDx by Rosetta Genomics is expected to close within the next several weeks and is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party. PersonalizeDx is a molecular diagnostics and services company serving community-based pathologists, urologists, oncologists and other reference laboratories across the U.S. The purchase price includes $2M in cash, 500,000 ordinary shares of Rosetta Genomics Ltd., some specified assets and certain services to be provided by Rosetta Genomics to Prelude Corporation. In connection with this transaction Rosetta Genomics will gain rights to market Prelude’s novel assay for ductal carcinoma in situ. On an annualized pro forma basis, including the operations of the PersonalizeDx business, Rosetta Genomics expects 2015 revenues to be in the range of $10M-$12M, and expects 2016 revenues to exceed $18M. Rosetta Genomics also expects to achieve positive EBITDA and positive cash flow from operations prior to the end of 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use